Literature DB >> 32794669

[Ilizarov metatarsal bone lengthening in treatment of diabetic foot ulcer complicated with chronic osteomyelitis of metatarsal head].

Baofeng Guo1, Wei Zhao1, Hongfei Wu1, Xibin Liang1, Zhiyang Xu1, Longxi Ren1, Sihe Qin2.   

Abstract

OBJECTIVE: To explore the effectiveness of the first-stage debridement and Ilizarov metatarsal bone lengthening in treatment of diabetic foot ulcer complicated with chronic osteomyelitis of metatarsal head.
METHODS: Between January 2015 and October 2018, 8 cases (9 feet, 11 sites) of diabetic foot ulcer complicated with chronic osteomyelitis of metatarsal head were treated by first-stage debridement and Ilizarov metatarsal bone lengthening. There were 3 males (4 feet, 5 sites) and 5 females (5 feet, 6 sites), with an average age of 57.5 years (range, 44-65 years). According to diabetic foot Wagner grade, 6 cases (7 feet) were grade 3 and 2 cases (2 feet) were grade 4. The chronic osteomyelitis located at left foot in 4 cases, right foot in 3 cases, and bilateral feet in 1 case. The duration of chronic osteomyelitis was 1-5 years (mean, 3.1 years). The chronic osteomyelitis site was the 1st metatarsal head in 3 feet, the 3rd metatarsal head in 1 foot, the 4th metatarsal head in 1 foot, and the 5th metatarsal head in 6 feet. Two patients had chronic osteomyelitis at 2 sites on 1 foot. The length of lengthened metatarsal bone, lengthening time, and the time of wearing external fixation frame were recorded, and the external fixation frame index was calculated. The healing conditions of foot ulcer and lengthening bone segment were observed, the healing time was recorded, and the healing index of lengthening bone was calculated. The ankle function was evaluated according to the American Orthopedic Foot and Ankle Society (AOFAS) score criteria.
RESULTS: All patients were followed up 9-26 months with an average of 15.0 months. Except pin tract infection during the bone lengthening period, there was no complications such as skin necrosis and vascular or nerve injury occurred during treatment. The length of lengthened metatarsal bone was 12-35 mm with an average of 20.5 mm; the metatarsal bone lengthening time were 21-84 days with an average of 57.8 days. The average time of wearing external fixation frame was 14.6 weeks (range, 10.4-21.1 weeks) and the external fixation frame index was 54.3 days/cm (range, 42.9-59.2 days/cm). The ulcer wound healed with an average healing time of 30.5 days (range, 19-70 days) and no ulcer recurrence was observed during follow-up. Bone healing was obtained in all bone lengthening segments, and the average healing index was 42.5 days/cm (range, 37-51 days/cm). The average AOFAS score was 91.7 (range, 87-95); 5 feet were excellent and 4 feet were good. The excellent and good rate was 100%.
CONCLUSION: The metatarsal bone lengthening under Ilizarov law of tension-stress after debridement can promote diabetic foot ulcers healing and reconstructing the length of metatarsal to retain the function of metatarsal load and avoid amputation. This is an effective method for the treatment of diabetic foot ulcer complicated with chronic osteomyelitis of metatarsal head.

Entities:  

Keywords:  Diabetic foot; Ilizarov technique; chronic osteomyelitis; metatarsal bone lengthening; metatarsal head; ulcer

Mesh:

Year:  2020        PMID: 32794669      PMCID: PMC8171897          DOI: 10.7507/1002-1892.201911070

Source DB:  PubMed          Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi        ISSN: 1002-1892


  14 in total

1.  One stage resection and pin stabilization of first metatarsophalangeal joint for chronic plantar ulcer with osteomyelitis.

Authors:  Jeffrey E Johnson; Sarah A Anderson
Journal:  Foot Ankle Int       Date:  2010-11       Impact factor: 2.827

2.  Conservative management of diabetic foot osteomyelitis.

Authors:  S Acharya; M Soliman; A Egun; S M Rajbhandari
Journal:  Diabetes Res Clin Pract       Date:  2013-07-11       Impact factor: 5.602

3.  [Elongation with callotaxis for congenital brachymetatarsia].

Authors:  S Guizar-Cuevas; F G Mora-Ríos; L C Mejía-Rohenes; A López-Marmolejo; J Cortés-Gómez
Journal:  Acta Ortop Mex       Date:  2010 Nov-Dec

Review 4.  Diabetic Foot Ulcers and Their Recurrence.

Authors:  David G Armstrong; Andrew J M Boulton; Sicco A Bus
Journal:  N Engl J Med       Date:  2017-06-15       Impact factor: 91.245

5.  Increased foot pressures after great toe amputation in diabetes.

Authors:  L A Lavery; D C Lavery; T L Quebedeax-Farnham
Journal:  Diabetes Care       Date:  1995-11       Impact factor: 19.112

6.  [The effectiveness of Ilizarov technique-based transverse tibial bone transport on treatment of severe diabetic foots complicated with systemic inflammation response syndrome].

Authors:  Puxiang Zhen; Yan Chen; Wei Gao; Zhenxun Lin; Zhaowei Zhong; Zhihai Teng; Lihuan He; Qikai Hua
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2018-10-15

7.  Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update).

Authors:  Sicco A Bus; Lawrence A Lavery; Matilde Monteiro-Soares; Anne Rasmussen; Anita Raspovic; Isabel C N Sacco; Jaap J van Netten
Journal:  Diabetes Metab Res Rev       Date:  2020-03       Impact factor: 4.876

8.  [Ilizarov external fixation without bone graft for atrophic femoral shaft nonunion].

Authors:  Baofeng Guo; Wei Zhao; Zhiyang Xu; Hongfei Wu; Lei Chen; Sihe Qin
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-08-15

9.  [Lesion clearance combined with Ilizarov technique for treatment of tophi in first metatarsophalangeal joint with bone defect].

Authors:  Boquan Qin; Shizhou Wu; Huiqi Xie; Fuguo Huang; Hui Zhang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-02-15

Review 10.  Inpatient management of diabetic foot disorders: a clinical guide.

Authors:  Dane K Wukich; David G Armstrong; Christopher E Attinger; Andrew J M Boulton; Patrick R Burns; Robert G Frykberg; Richard Hellman; Paul J Kim; Benjamin A Lipsky; James C Pile; Michael S Pinzur; Linda Siminerio
Journal:  Diabetes Care       Date:  2013-09       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.